Reformulating Injectables for Oral Delivery - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Reformulating Injectables for Oral Delivery
Could oral absorption-enhancing technologies change the shape of protein delivery?


Pharmaceutical Technology
Volume 35, Issue 10, pp. 48-56

References

1. J.H. Hochman, J.A. Fix, and E.L. LeCluyse, J. Pharm. Exp. Therap. 269 (2), 813–822 (1994).

2. E.G. Walsh, J.S. Fox, and T.W. Leonard, Pharm. Technol. 35 (4), s12–s14 (2011).

3. E. Merisko-Liversidge, S.L. McGurk, and G.G. Liversidge, Pharm. Res. 21 (9), 1545–1553 (2004).

4. C. Timpe, Am. Pharm. Rev. 11 (1), 12–21 (2010).

5. S. Eiamtrakarn et al., Biomater. 23 (1), 145–152 (2002).

6. J. Shaji and V. Patole, Indian J. Pharm. Sci. 70 (3), 269–277 (2008).

7. A.J. Almeida and E. Souto, Adv. Drug Deliv. Rev. 59 (6), 478–490 (2007).

8. S.V.R. Rao and J. Shao, Int. J. Pharm. 362 (1–2), 2–9 (2008).

9. S.V.R. Rao, P. Agarwal, and J. Shao, Int. J. Pharm. 362 (1–2), 10–15 (2008).

10. S.V.R. Rao, K. Yajurvedi, and J. Shao, Int. J. Pharm. 362 (1–2), 16–19 (2008).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
29%
Attracting a skilled workforce
27%
Obtaining/maintaining adequate financing
13%
Regulatory compliance
31%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Source: Pharmaceutical Technology,
Click here